Last quarter (Q4 2023), Evoke Pharma's total revenue was $1.68M, an increase of 110.45% from the same quarter last year. In Q4, Evoke Pharma's net income was $-1.99M. See Evoke Pharma’s key income statements, including revenue, expenses, profit, and income.

Income Statement	TTM	Dec 23	Dec 22	Dec 21	Dec 20	Dec 19
Total Revenue	$ 5.18M	$ 5.18M	$ 2.51M	$ 1.62M	$ 23.02K	$ 0.00
Cost of Revenue	-	-	-	-	$ 86.71K	$ 0.00
Gross Profit	$ 5.18M	$ 5.18M	$ 2.14M	$ 1.62M	$ -63.69K	$ 0.00
Operating Expense	$ 12.61M	$ 12.61M	$ -9.92M	$ 9.77M	$ 12.98M	$ 7.15M
Operating Income	$ -7.32M	$ -7.43M	$ -7.79M	$ -8.15M	$ -13.05M	$ -7.15M
Net Non Operating Interest Income Expense	$ -361.40K	$ -361.40K	$ -437.99K	$ -386.31K	$ -107.32K	$ 28.80K
Other Income Expense	-	-	-	-	-	-
Pretax Income	$ -7.49M	$ -7.39M	$ -8.22M	$ -8.54M	$ -13.15M	$ -7.13M
Tax Provision	-	-	-	-	-	-
Earnings From Equity Interest Net Of Tax	-	-	-	-	-	-
Net Income Common Stockholders	$ -7.72M	$ -7.79M	$ -8.22M	$ -8.54M	$ -13.15M	$ -7.13M
Basic EPS	$ -2.33	$ -2.33	$ -2.62	-	$ -6.24	$ -0.32
Diluted EPS	$ -2.33	$ -2.33	$ -2.62	$ -3.24	$ -6.24	$ -0.32
Basic Average Shares	$ 13.37M	$ 3.34M	$ 3.14M	$ 2.68M	$ 2.12M	$ 22.30M
Diluted Average Shares	$ 13.37M	$ 3.34M	$ 3.14M	$ 2.68M	$ 2.12M	$ 22.30M
Dividend Per Share	-	-	-	-	-	-
Total Operating Income As Reported	-	-	-	-	-	-
Reported Normalized Basic E P S	-	-	-	-	-	-
Reported Normalized Diluted E P S	-	-	-	-	-	-
Rent Expense Supplemental	-	-	-	-	-	-
Total Expenses	$ 12.61M	$ 12.61M	$ 10.29M	$ 9.77M	$ 13.07M	$ 7.15M
Net Income From Continuing And Discontinued Operation	$ -7.79M	$ -7.79M	$ -8.22M	$ -8.54M	$ -13.15M	$ -7.13M
Normalized Income	$ -4.14M	$ -5.84M	$ -5.91M	-	$ -13.15M	$ -7.13M
Interest Expense	-	-	-	-	$ 112.99K	$ 0.00
EBIT	$ -6.99M	$ -6.89M	$ -6.98M	$ -8.04M	$ -13.04M	$ -7.13M
EBITDA	$ -6.99M	$ -6.89M	$ -6.98M	$ -8.04M	$ -13.04M	$ -7.13M

Currency in USD

Evoke Pharma Earnings and Revenue History

Get More with TipRanks Premium

What's Included in PREMIUM?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing